Eli Lilly to Buy Merida Biosciences for Up to $2.875 Billion in Cash
The Cambridge, Massachusetts biotech's lead drug, MER511, is in Phase 1 testing for Graves' disease and thyroid eye disease; Lilly says the deal should close in the fourth quarter of 2026.
A $2.9 Billion Bet on a Drug That's Barely Left Its First Trial
Eli Lilly said on August 31, 2026 that it will pay up to $2.875 billion in cash to buy Merida Biosciences, a small, privately held biotech in Cambridge, Massachusetts[1][3]. The number sounds precise. It isn't quite what it looks like.
That $2.875 billion is a ceiling, not a check Lilly is writing today. It's made up of an upfront payment plus milestone payments that only arrive if Merida's drugs hit specific development targets[1][2]. Lilly hasn't said how the money splits between the two. So the number every headline is using is the most Lilly could pay, in the best case for Merida, not the price of the deal.
What Lilly actually gets right now is early science, not a finished product. Merida's lead drug, MER511, is in Phase 1, the first and smallest stage of human testing, mainly meant to check that a drug is safe rather than prove it works[1][8]. It's aimed at Graves' disease and thyroid eye disease, two conditions caused by the same problem: the immune system makes rogue antibodies that mistakenly switch on the thyroid[1]. Merida's other asset, MER769, is a potential allergy treatment that hasn't even been tested in a person yet[8]. Lilly expects the deal to close in the fourth quarter of 2026[1].
Why a Company Having Its Best Year Is Also Its Buying Spree
The deal makes more sense once you see the math behind Lilly's current success. In the second quarter of 2026, Lilly's revenue rose 48% to $23.0 billion, powered almost entirely by its weight-loss and diabetes drugs Mounjaro and Zepbound[15]. The company raised its full-year sales guidance to between $85 billion and $87 billion[15].
That kind of growth built on two drug franchises is a strength today and a risk tomorrow. Patents expire. Cheaper copies eventually arrive. Every large drugmaker in Lilly's position ends up doing the same thing: spending today's cash on tomorrow's medicine, while the cash is there to spend[5][9]. Merida is one more purchase in a year full of them. Bloomberg reported in May that Lilly had already announced more than $20 billion in acquisitions during 2026[5].
Trade outlets can't even agree on how many deals that is. Endpoints News called Merida "Lilly's 13th acquisition of 2026." BioSpace called the same deal Lilly's ninth, with total 2026 deal spending "approaching $29 billion"[6][7][10]. Neither outlet explains what it's counting, whether that means only outright buyouts or licensing deals too. The count varies because the rule for what qualifies as an "acquisition" isn't published anywhere.
The Number Nobody Will Say Out Loud
Here's the piece of the deal that matters most and that Lilly left out: how much of that $2.875 billion is guaranteed versus contingent. In biotech deals like this, the upfront payment is the money paid at signing. The milestone payments only get paid if the drug clears specific hurdles, like finishing a later trial or hitting a sales target[1][3].
For a Phase 1 drug, the upfront portion is typically the smaller slice. That means the real, committed cost to Lilly right now is probably well under $2.875 billion, though nobody outside the deal knows the exact figure. This structure exists because it splits the risk between buyer and seller. Merida's investors get paid more if the science pans out. Lilly pays less if it doesn't.
Wall Street analysts see that structure as a point in Lilly's favor. Leerink Partners analyst David Risinger called the purchase "further evidence of management's intent to diversify Lilly's pipeline beyond obesity[3]." BMO Capital Markets described it as a strategic use of capital that broadens Lilly's immunology pipeline[3]. Set against Lilly's $85-87 billion in expected 2026 sales, the maximum deal price is small, only about 3% of one year's revenue[1][15].
For Merida and its backers, the sale looks like a natural next step rather than a retreat. The company launched publicly in April 2025 with a $121 million Series A led by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures, and joined by GV and Perceptive Xontogeny Venture Funds[13][14]. Taking a Phase 1 drug through years of larger trials and an eventual launch costs vastly more than that initial raise. Selling to Lilly hands the company money and trial infrastructure Merida wouldn't have on its own[13].
A Crowded Field With One Recent Casualty
The disease Merida is chasing isn't an empty market. Thyroid eye disease already has an approved treatment, Amgen's Tepezza, sitting on pharmacy shelves[12]. Viridian Therapeutics has moved its own drug, veligrotug, toward the formal FDA application needed to sell it. Immunovant's batoclimab is trailing further behind in testing[12].
And one recent contender already failed at the finish line. Argenx, a competitor working on similar antibody biology, permanently stopped its late-stage studies of its drug efgartigimod in thyroid eye disease[11]. That's a serious result: it means promising early antibody science in this exact disease has already collapsed once at the stage that counts most, right before a possible approval. Trade coverage of the Merida deal tends to mention the argenx failure only as background color, not as a direct risk to MER511's own odds.
For patients, none of this changes anything in the near term. MER511 has only cleared the safety-focused first phase of testing. Even on the smoothest possible path, any approval is years away, and success in Phase 1 doesn't reliably predict what happens in later, larger trials[8][11].
Who Wins When Big Pharma Buys Instead of Builds
There's a broader argument playing out underneath this specific deal, and it isn't really about Merida at all. It's about whether giant drugmakers like Lilly are increasingly buying their innovation rather than growing it in-house. The data backs up the shift: big pharma's share of the industry's total drug research output fell from 72% in 2014 to roughly 40% in 2023, as small and newly formed biotech firms came to originate more than half of all new drugs entering clinical testing[9].
Critics of this pattern argue that when giant companies compete to buy a shrinking pool of promising small biotechs, prices for those companies rise, and the winning bidder eventually recoups that cost through what it charges for the drug[9]. Whether buying companies like Merida actually helps or hurts the acquirer's own research productivity is a genuinely open question. Academic studies on that point are mixed, some finding gains from folding in outside science, others finding none[9]. Underneath the innovation debate sits a real financial fact: a company like Lilly has every reason to want cheap access to promising science wherever it originates, whether that's grown in-house or bought.
None of this is unique to Lilly, and nothing about the deal suggests regulators see a competition problem in a company this size buying a Phase 1 drug in a crowded field[9]. The dispute over this deal was never really about whether Lilly broke any rules. It's about what a company with $85 billion in annual sales and thirteen, or nine, or somewhere-in-between acquisitions this year is actually solving for, and whether the next Merida-sized biotech gets to grow up independent or gets bought before anyone finds out.
Summary
Eli Lilly said on August 31, 2026 that it has agreed to buy Merida Biosciences, a privately held biotech in Cambridge, Massachusetts[1][3]. The price is up to $2.875 billion in cash — an upfront payment plus later payments that only happen if the drugs hit certain development goals[1][2]. Lilly did not say how the money splits between the two. That matters: the headline number is a maximum, not a check being written today. Lilly expects the deal to close in the fourth quarter of 2026[1].
What Lilly is buying is early-stage science, not a product on pharmacy shelves. Merida's lead candidate, MER511, is in Phase 1 — the first and smallest stage of human testing, where the main question is safety[1][8]. It is aimed at Graves' disease and thyroid eye disease. Both are driven by rogue antibodies the body makes against its own thyroid[1]. Merida also brings MER769, an allergy candidate that has not yet entered human testing at all[8].
The deal is Lilly's latest in a long run of 2026 purchases. Bloomberg reported in May that Lilly had already announced more than $20 billion in acquisitions this year as it looks past its obesity and diabetes drugs[5]. Trade outlets disagree on the exact count — Endpoints News called Merida Lilly's 13th acquisition of 2026, while BioSpace called it the ninth[6][7]. The counts differ because outlets draw the line differently between outright buyouts and licensing partnerships.
The genuine dispute is not over the facts of the deal — those come straight from Lilly's release. It is over what heavy buying means. Supporters, including sell-side analysts, say buying outside science is how a company sensibly spreads its bets and reduces its reliance on one franchise[3][4]. Critics of the broader pattern point to research showing big pharma's own share of industry drug R&D has shrunk sharply as small and emerging firms drive more of the innovation, though academic findings on whether acquisitions themselves help or hurt an acquirer's own research output are mixed[9]. A separate live question is whether MER511 works at all: a rival company, argenx, permanently stopped its late-stage thyroid eye disease program last year[11].
The Event
On August 31, 2026, Eli Lilly and Company announced a definitive agreement to acquire Merida Biosciences, a privately held biotechnology company based in Cambridge, Massachusetts[1][3]. Lilly said it will pay up to $2.875 billion in cash, made up of an upfront payment and milestone-based payments, and did not disclose the split between the two[1][2]. The acquisition brings Lilly MER511, a Phase 1 candidate for Graves' disease and thyroid eye disease, and MER769, a preclinical antibody aimed at allergic conditions[1][8]. Lilly said it expects the transaction to close in the fourth quarter of 2026[1].
Undisputed Facts
- Lilly announced the agreement on August 31, 2026, and stated the maximum value as up to $2.875 billion in cash, including an upfront payment and contingent milestone payments[1][2].
- Lilly did not disclose how much of the $2.875 billion is paid upfront versus tied to milestones[3][6].
- Merida's lead candidate, MER511, is in Phase 1 clinical development for Graves' disease and thyroid eye disease[1][8].
- Both conditions are driven by thyroid-stimulating immunoglobulins — autoantibodies that switch on the thyroid-stimulating hormone receptor[1].
- Merida also has MER769, a preclinical antibody aimed at allergic disease, with potential uses cited in food allergy, asthma and chronic spontaneous urticaria[8].
- Merida was founded in 2022 inside Third Rock Ventures and came out of stealth in April 2025 with a $121 million Series A co-led by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures, joined by GV and Perceptive Xontogeny Venture Funds[13][14].
- Bloomberg reported in May 2026 that Lilly had announced more than $20 billion in acquisitions during 2026[5].
- Argenx announced it was permanently discontinuing its late-stage UplighTED studies of subcutaneous efgartigimod in moderate-to-severe thyroid eye disease[11].
- Lilly reported second-quarter 2026 revenue of $23.0 billion, up 48%, driven mainly by Mounjaro and Zepbound volume, and raised full-year 2026 sales guidance to between $85 billion and $87 billion[15].
The Pressure
Strip away the moralizing and blame. What structural realities persist regardless of which narrative wins?
- The one-franchise problem
- Lilly's growth is concentrated in obesity and diabetes drugs. Q2 2026 revenue rose 48% to $23.0 billion, driven mainly by Mounjaro and Zepbound[15]. Concentration that heavy is a strength now and a liability later. Every large drugmaker facing this shape buys pipeline, regardless of what it says about innovation philosophy[5][9].
- Milestones move the real price
- In biotech deals, headline value is upfront cash plus milestone payments — money owed only if the drug clears specific development or sales targets. Lilly disclosed neither split[1][3]. For a Phase 1 asset, the upfront is typically the smaller share, meaning the true committed cost is likely well under $2.875 billion. The reason both sides accept this structure is that it splits the risk: the seller gets paid more if the science works, the buyer pays less if it doesn't.
- A narrow, crowded target
- Graves' disease and thyroid eye disease already have a marketed drug (Amgen's Tepezza), a filing-stage rival (Viridian's veligrotug), a trailing competitor (Immunovant's batoclimab), and a late-stage failure (argenx's efgartigimod)[11][12]. That combination means the clinical bar is real and the commercial window may be narrower by the time a Phase 1 drug arrives.
- Venture math
- Merida raised $121 million in April 2025 and agreed to sell about 16 months later[13]. Even if only part of $2.875 billion is upfront, that is a large multiple on a short timeline. That outcome is itself the incentive that funds the next wave of startups — which is why the buy-side pattern and the startup-formation pattern are the same system, not two separate ones.
Material realityA privately held company with two programs — one that has cleared only first-stage human safety testing and one that has not entered humans at all — is being bought by a drugmaker guiding to $85-87 billion in 2026 sales[1][8][15]. The maximum price of $2.875 billion equals roughly 3% of a single year's revenue, and the actual cash moving at closing is smaller and undisclosed[1][15]. No patient's treatment changes as a result of this announcement; MER511 would need years of additional trials before any approval decision. What is verifiably true regardless of framing: Lilly has announced a large number of acquisitions in 2026 — outlets count between nine and thirteen and put spending between $20 billion and $29 billion depending on what they include[5][6][7][10] — and the therapeutic area Lilly is entering has produced one high-profile late-stage failure already[11].
Narrative as a weaponThree groups are shaping how this reads. Lilly wants you to see a science story: precision medicine for people whose own antibodies are attacking their thyroid, with the price and the early stage as footnotes. Sell-side analysts want you to see a discipline story — cash from obesity drugs being recycled into future revenue, with the milestone structure as proof of restraint. Trade publications want you to see a volume story, and they compete on the count: 'ninth,' 'twelve,' '13th acquisition of 2026,' 'deal-hungry.' That count is the least solid number in the coverage, because no outlet publishes its inclusion rule. Note what almost nobody foregrounds: the drug has cleared only Phase 1, the closest late-stage competitor in the same disease was permanently discontinued, and the single figure that would tell you what Lilly actually committed today — the upfront payment — was not disclosed by anyone.
How Each Side Sees It
Each major actor’s view — how it frames things, its underlying incentive, and how it’s materially affected. Tap a side to read it.
Frames it asLilly's case is that one franchise, however large, is not a strategy. Obesity and diabetes drugs are carrying the company right now — Q2 2026 revenue rose 48% to $23.0 billion on Mounjaro and Zepbound[15]. But every drug eventually faces patent expiry and copycat competition. So the disciplined move, Lilly argues, is to spend today's cash on tomorrow's medicines while the cash exists. Lilly also frames Merida as a scientific fit, not just a purchase. Merida's platform is built on the Fc region of an antibody — the tail end that the immune system uses as a handle. Merida engineers that handle so it grabs harmful autoantibodies and flags them for the liver to destroy, and can also target the B-cells that make them[13][14]. That is a narrower approach than wiping out broad classes of antibodies, and Lilly's stated interest is precision: hit the bad antibody, leave the rest of the immune system alone[1].
WhyDiversify away from dependence on GLP-1 obesity and diabetes drugs before that market matures or gets crowded, and convert record current cash flow into a pipeline that pays out in the 2030s[3][5][15].
Impact on themUp to $2.875 billion in cash exposure, most of it likely deferred behind milestones that only pay if MER511 advances[1]. Set against Lilly's $85-87 billion full-year sales guidance, the deal is small — roughly 3% of one year's revenue at the maximum[15]. Lilly also absorbs the clinical risk of an asset that has only cleared the first human safety stage[8].
Frames it asMerida's argument is that its science advanced fast and now needs a partner with global reach. The company launched publicly in April 2025 with $121 million and started a Phase 1 trial of MER511 in December, reporting what trade coverage described as substantial reductions in thyroid-stimulating antibodies with a favorable early safety profile[8][13]. From the founders' and investors' side, selling to Lilly is not a retreat: taking a Phase 1 drug through late-stage trials and a global launch costs far more than a Series A, and Lilly can fund and run that. Third Rock Ventures, Bain Capital Life Sciences, BVF Partners, GV and Perceptive Xontogeny Venture Funds put up the $121 million that got the drug into humans[13].
WhyReturn capital to venture investors at a strong multiple over the $121 million raised, while giving the lead program the money and trial infrastructure it needs to reach patients[13].
Impact on themMerida's shareholders receive an undisclosed upfront cash payment now and could receive more if milestones are met[1]. Because the split is not disclosed, the actual realized return is not publicly checkable.
Frames it asThe market-facing view is that this is exactly the deal shape investors should want: small relative to the balance sheet, structured so most of the money is contingent, and pointed at a therapeutic area Lilly already knows. Leerink Partners analyst David Risinger called it 'further evidence of management's intent to diversify Lilly's pipeline beyond obesity'[3]. BMO Capital Markets described it as a strategic use of capital that fits earlier business development and broadens the immunology and inflammation pipeline[3]. The steelman here is about risk pricing, not enthusiasm: a milestone-heavy structure means Lilly pays the full $2.875 billion only in the scenario where the drug works, which is the scenario where it is worth it.
WhyJudge whether Lilly's obesity earnings are being reinvested in assets that can eventually replace them, rather than paid out or spent on premium-priced deals[3][4].
Impact on themCumulative 2026 deal spending — reported by different outlets as more than $20 billion, roughly $25 billion, and approaching $29 billion including milestones — reduces cash available for buybacks or dividends and raises integration risk[5][6][10].
Frames it asThis camp's argument is not that any single deal is wrong. It is that a pattern has replaced a function. Big pharma's own share of industry drug R&D output fell from 72% in 2014 to roughly 40% in 2023, as small and emerging firms came to originate more than half of new drugs entering the clinic[9]. Critics argue that when the biggest firms bid against each other for a shrinking pool of clinical-stage biotechs, prices rise, the winner books the cost, and the cost eventually shows up in what the drug is priced at. Academic studies on whether acquisitions themselves improve or hurt an acquirer's own research productivity are mixed, with some finding productivity gains from external assets and others finding no innovation synergy[9]. The values claim underneath is about who captures the return on science that often started with public research funding.
WhyConstrain drug prices and press large drugmakers to sustain in-house discovery rather than outsourcing it to venture-funded startups they later buy[9].
Impact on themLittle direct leverage over a private, all-cash deal of this size. There is no indication in the sources reviewed that antitrust regulators have raised concerns about this transaction, and a Phase 1 asset in a field with several competitors is an unlikely target for a competition challenge.
Frames it asFor patients, the relevant fact is that this field has recently produced both progress and failure. Amgen's Tepezza is the established marketed treatment for thyroid eye disease[12]. Viridian Therapeutics moved veligrotug toward a Biologics License Application — the formal FDA application to sell a biologic drug — and Immunovant's batoclimab is further back in the clinic[12]. Argenx, meanwhile, permanently stopped its late-stage thyroid eye disease studies of efgartigimod[11]. Advocates for patients argue more shots on goal is straightforwardly good, because current options are limited and some patients do not respond. Skeptics of hype argue the argenx result is a warning that promising antibody biology in this disease has already failed once at the stage that counts.
WhyGet more effective and better-tolerated options for conditions that can cause vision loss and thyroid dysfunction[1][12].
Impact on themNo near-term change. MER511 is in Phase 1; even on a smooth path, approval would be years away, and Phase 1 success does not predict later results[8][11].
Like this article?
The Bias Ledger average rating 4
The same story, as framed by outlets across the spectrum, ordered least to most biased. The bias score (1 = straight, 10 = heavily spun) is an AI assessment of that framing — click an outlet to see its track record. The tell is the word choice or omission that reveals the angle.
| Outlet | Vantage | Bias | How they frame it | The tell |
|---|---|---|---|---|
| Reuters | International wire, U.S. center | 2 | "Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push" | Straight wire construction: 'up to' is kept in the headline, which correctly signals a ceiling rather than a price. 'Push' is mild characterization but does no editorial work. Notes the undisclosed terms rather than glossing over them. |
| CNBC | U.S. center, business audience | 3 | "Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push" | Frames the deal through the investor lens — 'acquisition spree,' 'windfall profits' from weight-loss drugs — and gives analyst reaction (Leerink, BMO) prominence. Both quoted analysts are supportive; no skeptical analyst voice appears, so the read is one-sided by selection rather than by wording. |
| Fierce Biotech | U.S. biotech trade | 3 | "Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies" | Strongest on the actual science — explains the autoantibody mechanism and names MER769 — but drops the 'up to' qualifier in the headline, stating $2.88B as the price rather than the ceiling. |
| Endpoints News | U.S. biotech trade | 4 | "Lilly to buy TED startup Merida Biosciences in its 13th acquisition of 2026" | Puts the count in the headline, which makes deal volume the story. The '13th' figure conflicts with other trade outlets' counts of nine or twelve for the same deal, and the headline does not define what is being counted — outright buyouts, licensing pacts, or both. |
| Eli Lilly and Company | Corporate primary source | 5 | "Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases" | The headline leads with patient benefit, not with the price or the stage of development. It says 'advance treatments' for a drug that has only completed early safety testing. The release also declines to split upfront from milestone money — the single number most useful for judging what Lilly actually committed. |
| BioSpace | U.S. biotech trade | 5 | "Deal-hungry Lilly strikes up to $2.9B immuno play for Merida" | 'Deal-hungry' and 'play' are appetite words. They frame Lilly as compulsive rather than strategic without attributing that judgment to anyone. Rounds $2.875 billion up to '$2.9B' in the headline. |
| The Motley Fool | U.S. retail-investor advocacy | 6 | "Eli Lilly Is Acquiring Merdia Biosciences for Up to $2.88 Billion. Here's What That Means for Investors." | Explicitly written to answer 'should I buy the stock,' which is a different question from 'what happened.' The headline as published also misspells Merida — a small signal about editing standards on a fast-turn piece. |
References
- Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases — Eli Lilly and Company · Primary source; the acquiring company's own investor-relations release
- Lilly to Acquire Merida Biosciences for $2.875B — Contract Pharma · Pharmaceutical manufacturing trade publication, industry-funded via advertising
- Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push — CNBC · U.S. center, business/investor audience; NBCUniversal-owned
- Eli Lilly Is Acquiring Merdia Biosciences for Up to $2.88 Billion. Here's What That Means for Investors. — The Motley Fool · U.S. retail-investor advocacy; subscription stock-picking business
- Eli Lilly Commits Over $20 Billion to Acquisitions in 2026 Expansion Drive — Bloomberg · U.S. center, financial-terminal business model
- Deal-hungry Lilly strikes up to $2.9B immuno play for Merida — BioSpace · U.S. biotech trade; revenue from job listings and industry advertising
- Lilly to buy TED startup Merida Biosciences in its 13th acquisition of 2026 — Endpoints News · U.S. biotech trade; paid-subscription model aimed at industry insiders
- Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies — Fierce Biotech · U.S. biotech trade; advertising-supported, Questex-owned
- No Contest: Small Pharma Innovates Better than Big Pharma — FREOPP (Foundation for Research on Equal Opportunity) · Free-market think tank whitepaper; documents big pharma's shrinking share of industry R&D output relative to small/emerging firms — not a neutral academic arbiter, and does not itself claim acquisitions hurt acquirer innovation
- Lilly's $25B+ M&A spree captures half of pharma's 2026 capacity — BioSpace · U.S. biotech trade; revenue from job listings and industry advertising
- Argenx permanently grounds studies of high-flying Vyvgart in thyroid eye disease — Fierce Pharma · U.S. pharma trade; advertising-supported, Questex-owned
- Thyroid Eye Disease Treatment: What's on the Horizon? — DelveInsight · Commercial pharma market-research firm; sells pipeline reports to industry clients
- Third Rock-backed Merida launches with $121M series A to fund autoimmune pipeline — Fierce Biotech · U.S. biotech trade; advertising-supported, Questex-owned
- Merida Biosciences Launches with $121M to Create Therapeutics for Multiple Autoimmune and Allergic Diseases — Business Wire · Primary source; company-issued press release distribution
- Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress — Eli Lilly and Company · Primary source; company earnings release